First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
; : 120-126, 2018.
Article
ي Ko
| WPRIM
| ID: wpr-738961
المكتبة المسؤولة:
WPRO
ABSTRACT
BACKGROUND/AIMS:
The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70~85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. MATERIALS ANDMETHODS:
Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy.RESULTS:
This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001).CONCLUSIONS:
Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Breath Tests
/
Medical Records
/
Retrospective Studies
/
Helicobacter pylori
/
Helicobacter
/
Disease Eradication
نوع الدراسة:
Guideline
/
Observational_studies
المحددات:
Humans
اللغة:
Ko
مجلة:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
السنة:
2018
نوع:
Article